Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

Exemestane (Exe) in combination with Everolimus (Eve) represents an important treatment option for patients diagnosed with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC), which was previously treated with non-steroidal aromat...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccardi, Ferdinando, Colantuoni, Giuseppe, Diana, Anna, Mocerino, Carmela, Cartenì, Giacomo, Lauria, Rossella, Febbraro, Antonio, Nuzzo, Francesco, Addeo, Raffaele, Marano, Ombretta, Incoronato, Pasquale, De Placido, Sabino, Ciardiello, Fortunato, Orditura, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109668/
https://www.ncbi.nlm.nih.gov/pubmed/30155246
http://dx.doi.org/10.3892/mco.2018.1672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109668/
https://www.ncbi.nlm.nih.gov/pubmed/30155246
http://dx.doi.org/10.3892/mco.2018.1672

Ejemplares similares